Zions Bancorporation’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $26.3K | Buy |
329
+109
| +50% | +$9.44K | ﹤0.01% | 475 |
|
|
2024
Q3 | $19.8K | Sell |
220
-140
| -39% | -$11.8K | ﹤0.01% | 520 |
|
|
2024
Q2 | $28.3K | Sell |
360
-69
| -16% | -$5.66K | ﹤0.01% | 493 |
|
|
2024
Q1 | $37.4K | Sell |
429
-49,248
| -99% | -$4.2M | ﹤0.01% | 463 |
|
|
2023
Q4 | $4.09M | Buy |
49,677
+887
| +2% | +$67.6K | 0.28% | 64 |
|
|
2023
Q3 | $3.82M | Buy |
48,790
+8,594
| +21% | +$719K | 0.34% | 52 |
|
|
2023
Q2 | $3.54M | Sell |
40,196
-550
| -1% | -$47.4K | 0.3% | 61 |
|
|
2023
Q1 | $3.28M | Buy |
40,746
+5,139
| +14% | +$419K | 0.28% | 66 |
|
|
2022
Q4 | $2.77M | Buy |
35,607
+25,557
| +254% | +$2.07M | 0.22% | 73 |
|
|
2022
Q3 | $811K | Sell |
10,050
-65
| -0.6% | -$5.84K | 0.09% | 169 |
|
|
2022
Q2 | $908K | Sell |
10,115
-2,985
| -23% | -$302K | 0.09% | 161 |
|
|
2022
Q1 | $1.45M | Buy |
13,100
+2,843
| +28% | +$300K | 0.13% | 111 |
|
|
2021
Q4 | $1.06M | Buy |
10,257
+1,794
| +21% | +$208K | 0.09% | 133 |
|
|
2021
Q3 | $1.06M | Buy |
8,463
+2,560
| +43% | +$331K | 0.11% | 106 |
|
|
2021
Q2 | $732K | Buy |
5,903
+623
| +12% | +$78.2K | 0.07% | 134 |
|
|
2021
Q1 | $624K | Buy |
5,280
+2,245
| +74% | +$263K | 0.07% | 132 |
|
|
2020
Q4 | $355K | Buy |
3,035
+630
| +26% | +$69.4K | 0.04% | 172 |
|
|
2020
Q3 | $250K | Buy |
2,405
+52
| +2% | +$5.22K | 0.04% | 189 |
|
|
2020
Q2 | $215K | Sell |
2,353
-37
| -2% | -$3.55K | 0.03% | 205 |
|
|
2020
Q1 | $215K | Sell |
2,390
-711
| -23% | -$75.6K | 0.04% | 166 |
|
|
2019
Q4 | $352K | Buy |
3,101
+379
| +14% | +$41.6K | 0.05% | 132 |
|
|
2019
Q3 | $295K | Sell |
2,722
-427
| -14% | -$44.6K | 0.04% | 168 |
|
|
2019
Q2 | $307K | Sell |
3,149
-564
| -15% | -$51.5K | 0.04% | 154 |
|
|
2019
Q1 | $338K | Sell |
3,713
-237
| -6% | -$21.2K | 0.05% | 135 |
|
|
2018
Q4 | $360K | Buy |
+3,950
| New | +$369K | 0.26% | 49 |
|
|
2018
Q3 | – | Sell |
-5,073
| Closed | -$434K | – | 817 |
|
|
2018
Q2 | $434K | Buy |
+5,073
| New | +$424K | 0.3% | 54 |
|
|
2017
Q4 | – | Sell |
-9,227
| Closed | -$717K | – | 829 |
|
|
2017
Q3 | $717K | Sell |
9,227
-4,365
| -32% | -$362K | 0.1% | 112 |
|
|
2017
Q2 | $1.21M | Sell |
13,592
-2,439
| -15% | -$206K | 0.21% | 63 |
|
|
2017
Q1 | $1.29M | Sell |
16,031
-7,151
| -31% | -$559K | 0.24% | 49 |
|
|
2016
Q4 | $1.65M | Sell |
23,182
-288
| -1% | -$22.6K | 0.29% | 49 |
|
|
2016
Q3 | $1.96M | Sell |
23,470
-593
| -2% | -$51.7K | 0.37% | 37 |
|
|
2016
Q2 | $2.13M | Buy |
24,063
+366
| +2% | +$29.6K | 0.37% | 37 |
|
|
2016
Q1 | $1.88M | Sell |
23,697
-808
| -3% | -$60.9K | 0.34% | 40 |
|
|
2015
Q4 | $1.83M | Buy |
24,505
+2,473
| +11% | +$186K | 0.32% | 43 |
|
|
2015
Q3 | $1.66M | Sell |
22,032
-1,070
| -5% | -$78.8K | 0.31% | 45 |
|
|
2015
Q2 | $1.71M | Buy |
23,102
+700
| +3% | +$53.5K | 0.27% | 54 |
|
|
2015
Q1 | $1.75M | Buy |
+22,402
| New | +$1.7M | 0.3% | 47 |
|
Other funds holding MDT
Zions Bancorporation's MDT Position: Q4 2024 in Review
Zions Bancorporation increased its Medtronic (MDT) stake by 50% in Q4 2024, buying an estimated $9.44K and bringing the position to 329 shares worth $26.3K. The position accounts for ﹤0.01% of the portfolio, ranked #475.
Zions Bancorporation first reported a position in MDT in Q1 2015 and has held it in 37 quarters since. The position peaked at $4.09M in Q4 2023. 2,124 funds tracked by Wall St. Rank hold MDT as of Q4 2024.
- Zions Bancorporation held 329 shares of Medtronic worth $26.3K as of Q4 2024.
- Zions Bancorporation bought 109 Medtronic shares in Q4 2024, an estimated $9.44K.
- Medtronic made up ﹤0.01% of Zions Bancorporation's portfolio in Q4 2024, its #475 holding.
- Zions Bancorporation first reported a position in Medtronic in Q1 2015 and has held it in 37 quarters since.
- Zions Bancorporation's Medtronic position peaked at $4.09M in Q4 2023.
- 2,124 funds tracked by Wall St. Rank held Medtronic as of Q4 2024.
Based on Zions Bancorporation's 13F filing for Q4 2024, filed 11 Feb 2025.